Evaluating the Early Efficacy and Safety of Ritlecitinib in Moderate Alopecia Areata: A Real-World, Single-Center Study

This file provides supplementary data for Evaluating the Early Efficacy and Safety of Ritlecitinib in Moderate Alopecia Areata: A Real-World, Single-Center Study. It includes: (1) one illustrative figure demonstrating a representative patient’s clinical response after 16 weeks of treatment, (2) a table summarizing treatment response in eyebrow and eyelash involvement, and (3) a comparative table of baseline demographics and disease characteristics between patients who achieved SALT50 at week 16 and those who did not. These materials support the main findings by offering detailed insights into subgroup responses and potential predictors of efficacy.